New Daily Persistent Headache
1
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Eli Lilly and CompanyINDIANAPOLIS, IN
1 programNew Daily Persistent Headache Biomarkers StudyN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AbbVieOnabotulinumtoxinA
Eli Lilly and CompanyNew Daily Persistent Headache Biomarkers Study
Clinical Trials (2)
Total enrollment: 14 patients across 2 trials
OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study
Start: Sep 2014Est. completion: Oct 20166 patients
Phase 2Terminated
New Daily Persistent Headache Biomarkers Study
Start: May 2018Est. completion: Nov 20218 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.